Table 2.

Multivariate analyses

Variables	NRM			Relapse			DFS			OS
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Entire cohort
Age at alloBMT	1.04	1.01-1.07	.016				1.02	1.00-1.04	.0292	1.02	1.00-1.04	.0167
HCT-CI 1-2 vs 0										1.39	0.75-2.6	.2975
HCT-CI ≥3 vs 0										2.1	1.17-3.77	.0127
Bu/Flu vs Bu/Cy							0.61	0.35-1.08	.091
Active disease vs morphologic CR				2.31	1.46-3.64	.0003	1.55	1.05-2.29	.0279
Patient CMV serology positive vs negative	2.74	1.33-5.66	.0063				1.66	1.15-2.40	.0073	1.44	0.96-2.16	.081
Donor CMV serology positive vs negative				1.63	1.05-2.53	.03
TNC dose				0.79	0.67-0.93	.005	0.82	0.71-0.95	.0066	0.79	0.68-0.92	.0018
AML patients
Age at alloBMT	1.04	1-1.07	.032				1.01	0.99-1.03	.2568	1.01	0.99-1.04	.2352
HCT-CI 1-2 vs 0							1.52	0.71-3.25	.2831	1.51	0.69-3.32	.303
HCT-CI ≥3 vs 0							1.9	0.96-3.78	.0662	1.82	0.89-3.71	.0986
Bu/Flu vs Bu/Cy							0.48	0.21-1.11	.0858	0.39	0.14-1.08	.0699
Active disease vs morphologic CR				2.51	1.35-4.66	.0036	2.26	1.39-3.67	.001	1.87	1.12-3.12	.0159
Patient CMV serology positive vs negative	4.13	1.58-10.8	.0038				1.91	1.16-3.13	.0105	1.61	0.96-2.71	.0696
TNC dose				0.75	0.59-0.95	.018	0.77	0.64-0.94	.0095	0.74	0.6-0.91	.0035
Cytogenetics* adverse vs favorable/intermediate				2.7	1.46-4.98	.0015	2.2	1.31-3.7	.0028	2.16	1.27-3.68	.0044

^*By refined MRC criteria as per Grimwade et al.²⁹